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We have previously established in a large retrospective
study that MSI testing was an effective first screen for
the identification of individuals with Lynch syndrome
(LS) in colorectal cancer (CRC) patients aged < 60
years. From these findings, MSI and/or IHC screening
was recommended for all newly diagnosed CRC patients
aged < 60 years in Western Australia, regardless of
family history of cancer. We have subsequently evalu-
ated the utility of routine MSI/IHC screening in diag-
nostic pathology laboratories for the detection of
previously undiagnosed individuals and families with LS.
From January 2009 to December 2010, 270 tumours
were tested for MSI and expression of MLH1, PMS2,
MSH2 and MSH6 using IHC. Cases showing MSI and/
or loss of expression were also tested for BRAF V600E
mutation. Seventy cases were found to have MSI, of
which 25 were excluded from further investigation as
possible LS cases due to the presence of the BRAF
V600E mutation. The remaining 45 “red flag” cases were
eligible for germline testing based on their MSI, IHC
and BRAF status. From 26 cases tested to date, 11 germ-
line mutations have been found. Nine were from indivi-
duals not previously recognized as LS and two were
untested members from known LS families. Extrapola-
tion of the mutation incidence (11/26, 42%) to all red
flag cases (n=45) suggests approximately 19 mutation
carriers in this cohort. This value approximates the
number of LS cases that could be expected to arise in
the Western Australian population over a two-year per-
iod (n=24), assuming that 1% of all CRCs are due to LS.
Our preliminary findings following the implementation
of state-wide routine MSI and IHC testing in Western
Australia indicate that the majority of LS cases are
being identified.
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